ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Acumen Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$1.77+0.08 (+4.73%)

Close on Oct 19, 2026

Market cap: $127.88M
P/E (TTM): –
Dividend yield: –

Acumen Pharmaceuticals, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Stock-Based Compensation	9.85	9.64	6.15	3.06	0.92	0.15
Change in Accounts Payable	-5.09	4.27	-0.26	0.55	0.56	0.31
Operating Cash Flow	-116	-86	-43	-35	-18	-7.45
Capital Expenditures	-0.09	-0.02	-0.02	-0.16	-0.04	–
Sale of Property, Plant & Equipment	–	0	0.00	0	–	–
Purchase of Investments	-38	-171	-251	-42	-104	–
Sale & Maturity of Investments	172	219	79	81	0	–
Investing Cash Flow	134	48	-172	39	-104	–
Stock Issued	0	7.94	122	3.79	169	–
Debt Issued	–	0	30	0	–	–
Taxes Paid on Share-Based Awards	-0.07	-0.04	0	–	–	–
Financing Cash Flow	-0.03	6.93	152	3.91	200	45
Free Cash Flow	-116	-86	-43	-35	-18	–
Income Taxes Paid	0	0	0	0	0	0
Interest Paid	2.94	2.97	0.17	0	0	0

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -96.2%

Financial strength

Current ratio: 2.47
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 126.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.23
Dividend yield: –